TrialBMJ open2018

Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.

Aideen M Campbell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.